Keryx Biopharmaceuticals to Host Conference Call of Third Quarter 2016 Financial Results on Wednesday, November 9, 2016
November 01 2016 - 9:15AM
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical
company focused on bringing innovative medicines to market for
people with renal disease, today announced that it will host a
conference call and webcast on Wednesday, November 9, 2016 at 8:00
a.m. ET to discuss its third quarter 2016 financial results and
provide corporate updates.
To participate in the conference call, please
dial 1-888-396-2320 (U.S.), 1-774-264-7560 (international) and
refer to conference ID: 11829223. The call will be webcast live
with slides and accessible through the Investors section of the
company’s website at www.keryx.com for a period of 15 days after
the call.
Keryx Biopharmaceuticals will announce its financial results for
this period in a press release to be issued prior to the call.
About Keryx Biopharmaceuticals, Inc. Keryx
Biopharmaceuticals, with headquarters in Boston, is focused on
bringing innovative medicines to market for people with renal
disease. In December 2014, the company launched its first
FDA-approved medicine, Auryxia® (ferric citrate) in the United
States. In January 2014, ferric citrate was approved for use
in Japan, where it is being marketed as Riona® by Keryx's Japanese
partner, Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd. In
September 2015, the European Commission granted European market
authorization for Fexeric® (ferric citrate coordination complex).
For more information about Keryx, please visit www.keryx.com.
Keryx Biopharmaceuticals Contact:
Lora Pike
Senior Director, Investor Relations
T: 617.466.3511
lora.pike@keryx.com
Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Historical Stock Chart
From Sep 2023 to Sep 2024